Fennec Pharmaceuticals
FENC
119 hedge funds and large institutions have $191M invested in Fennec Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 7 closing their positions.
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
156% more capital inflows, than outflows
Capital inflows: $30.4M | Capital outflows: $11.9M
16% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 32
13% more funds holding
Funds holding: 105 → 119 (+14)
4.5% more ownership
Funds ownership: 46.77% → 51.27% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCA
Prospect Capital Advisors
Sausalito,
California
|
+$4.27M |
| 2 |
Essex Investment Management
Boston,
Massachusetts
|
+$3.5M |
| 3 |
BlackRock
New York
|
+$3.37M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$2.14M |
| 5 |
CenterBook Partners
Greenwich,
Connecticut
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Solas Capital Management
Darien,
Connecticut
|
-$5.01M |
| 2 |
Jane Street
New York
|
-$1.94M |
| 3 |
CC
Cornerstone Capital
Palo Alto,
California
|
-$1.13M |
| 4 |
Trexquant Investment
Stamford,
Connecticut
|
-$943K |
| 5 |
Quadrature Capital
London,
United Kingdom
|
-$666K |
FENC Hedge Fund Activity: Q3 2026 in Review
119 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2026, worth a combined $191M — up 9.3% from $175M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FENC positions and 7 closed out — a net gain of 15 holders — while 37 added to existing stakes and 32 trimmed.
The largest buyer was Prospect Capital Advisors, adding an estimated $4.27M. The largest seller was Solas Capital Management, cutting an estimated $5.01M.
- 119 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2026, up from 105 in Q2 2026.
- Funds reported $191M of Fennec Pharmaceuticals stock for Q3 2026, up 9.3% quarter-over-quarter.
- 22 funds opened new Fennec Pharmaceuticals positions in Q3 2026 and 7 closed out, a net change of +15 holders.
- The largest Fennec Pharmaceuticals buyer in Q3 2026 was Prospect Capital Advisors, an estimated $4.27M added.
- The largest Fennec Pharmaceuticals seller in Q3 2026 was Solas Capital Management, an estimated $5.01M sold.
Based on aggregated 13F filings for Q3 2026.